



Dr. Rafael Navarro

Retina and Vitreous Department of the IMO, Institute of Ocular Microsurgery

Lecturer in the Master's Vitreous and Retina Degree of the Institute of Ocular Microsurgery and member of the Clinical Research Ethical Committee (CEIC) of the IMO

License Number: 28.468

Curriculum

Professional Profile

Partner and doctor specialising in the retina at the Ocular Microsurgery Institute, spokesperson for the IMO Foundation and associate professor on the Master's Course in Retina and Vitreous run by the IMO and the Faculty of Medicine at the Autonomous University of Barcelona, as well as a part-time teacher on the retina modules at the ESASO.

President of the Clinical Research Ethics Committee (CREC) and the Academic Personnel Committee at the Institute.

An expert in retinal medicine, his subject area and research focuses on macular diseases with special interest in age-related macular degeneration (AMD), hereditary retinal dystrophies and diabetic retinopathy. Collaborator on many international multicentre clinical trials related to these pathologies.

He was an Observer at the Vitreous-Retina-Macula Consultants of New York, USA, in 2006.

IMO
instituto de
microcirugía
ocular

Training

Rafael Navarro earned his undergraduate degree in Medicine and Surgery from the Autonomous University of Barcelona in 1990.

He later undertook his residency at the Ophthalmology Department of Valle de Hebrón Hospital (Autonomous University of Barcelona) under Dr Corcóstegui.

Specialisation

He is a retina specialist.

Professional Appointments

Staff doctor in the Ophthalmology Department of Juan XXIII Hospital of Barcelona.

Staff doctor in the Vitreoretinal Department of San Pablo Hospital and the Clinical Hospital of Barcelona.

He joined the Vitreoretinal Department of the IMO in 2000.

Teaching

He has been an associate lecturer in Ophthalmology at Rovira i Virgili University of Tarragona.

Research

His subject area and research focuses on macular diseases with special interest in age-related macular degeneration (AMD), hereditary retinal dystrophies and diabetic retinopathy.

On these subjects he has collaborated in numerous international multi-centric clinical trials. Most recently:

IMO
instituto de
microcirugía
ocular

Main researcher. FOVISTA (OPH-1004B)

Main researcher. BIOIMAGE (IMO- AFLI-2013-01)

Main researcher. SPECTRI (GX29185)

Main researcher. CEDAR. Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration. (150998-005)

Collaborator researcher. NEUTON (AFLI -2014-01)

Collaborator researcher. HARRIER. PHASE III (RTH-258-C002)

Collaborator researcher. AQUA. "Open-label Phase-IV study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment". (BAY 86-5321 /17850)

Collaborator researcher. AZURE. An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD). (BAY 86-5321 /16598)

Collaborator researcher. ATLANTIC (ECR-AMD-2015-09)

Collaborator researcher. VIOLET. An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME). (17613)

Collaborator researcher. IRIS 2. Compensation for blindness with the Intelligent Retinal Implant System (IRIS V2) in patients with retinal dystrophy. (CPP1E_Rev2)

Collaborator researcher. Identification of new retinal dystrophy genes and characterisation of genotype/phenotype correlations.

Affiliations

- American Academy of Ophthalmology (AAO)
- Club Jules Gonin
- European Society of Retina Specialists (EURETINA)
- Catalanian Ophthalmology Society (SCOFT)
- Spanish Ophthalmology Society (SEO).
- Spanish Retina and Vitreous Society (SERV).

Publications

Varano M, Eter N, Winyard S, Wittrup-Jensen KU, **Navarro R.**, Heraghty J. “The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD Patient and Caregiver Survey “. Clin Ophthalmol. 2016 Feb 3;10:257-67.

Burés-Jelstrup A., **Navarro R.** Comprender la Degeneración Macular Asociada a la Edad. Amat Editorial, Barcelona 2015

Varano M, Eter N, Winyard S, Wittrup-Jensen KU, **Navarro R.**, Heraghty J. “Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey “.Clin Ophthalmol. 2015 Dec 1;9:2243-50.

Mazzarella S, Mateo C, Freixes S, Burés-Jelstrup A, Rios J, **Navarro R.**, García-Arumí J, Corcóstegui B, Arrondo E. “Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema”. Ophthalmic Res. 2015;54(3):143-9. doi: 10.1159/000438759. Epub 2015 Sep 23.

Medeiros MD, Alkabes M, **Navarro R.** Garcia-Arumí J, Mateo C, Corcóstegui B. *Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema.* J Ocul Pharmacol Ther. 2014 Nov;30(9):709-16. doi: 10.1089/jop.2014.0010. Epub 2014 Sep 26. PubMed PMID: 25259834.

Dutra Medeiros M, Postorino M, **Navarro R.** Garcia-Arumí J, Mateo C, Corcóstegui B. *Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema.* Ophthalmologica. 2014;231(3):141-6. doi: 10.1159/000356413. Epub 2013 Dec 19. PubMed PMID: 24356099.

Dutra Medeiros M, Postorino M, **Navarro R**, Garcia-Arumí J, Mateo C, Corcóstegui B. *Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema*. Ophthalmologica. 2013 Dec 19. [Epub ahead of print] PubMed PMID: 24356099.

Dutra Medeiros M, **Navarro R**, Garcia-Arumí J, Mateo C, Corcóstegui B. *Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome*. Invest Ophthalmol Vis Sci. 2013 May 7;54(5):3320-4. PubMed PMID: 23599334

Navarro R, Burés-Jelstrup A. Inherited retinal pigmentary degenerations and inherited macular dystrophies. En: Medical Retina. ESASO Course Series Vol 1. Bandello F, Corcóstegui, B. Karger, Basel, 2012.

Navarro R, Burés-Jelstrup A, Vásquez LM, Mateo C, Nau J, Corcóstegui B. Radiation maculopathy after epimacular brachytherapy for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retinal Cases & Brief Reports 2011; 5:352 – 354.

García-García G, Aparisi MJ, Jaijo T, Rodrigo R, León AM, Ávila-Fernández A, Blanco-Kelly F, Bernal S, Navarro R, Diaz-Llopis M, Baiget M, Ayuso C, Millan JM, Aller E. Mutational screening of the USH2A gene in Spanish USH patients reveals 23 novel pathogenic mutations. Orphanet J Rare Dis. 2011 Oct 17; 6:65.

Pomares E, Burés-Jelstrup A, Ruiz-Nogales S, Corcóstegui B, González-Duarte R, Navarro R. Nonsense-mediated decay as the molecular cause for autosomal recessive bestrophinopathy in two unrelated families. Invest Ophthalmol Vis Sci. 2012 Jan 31; 53(1):532-7.

Mateo C, Burés-Jelstrup A, Navarro R, Corcóstegui B. Macular buckling for eyes with myopic foveoschisis secondary to posterior staphyloma. Retina. 2012 Jun; 32(6):1121-8.

Navarro R., Gris O., Broc L., Corcostegui B., “Bilateral giant retinal tear following posterior chamber phakic intraocular lens implantation”. Journal of Refractive Surgery. May-jun; 21(3): 298-300.2005.

Navarro R., Mateo C., Corcóstegui B., Baiget M., Bernal S.R., “Choroidal Neovascularization associated with Goldmann-Favresyndrome”. Retinal cases&brief reports. 2007.

Navarro R., Cassarol R., Mateo C., Gris O., Adan A., Corcóstegui B., "Optical Coherence Tomography Findings in Alport Syndrome". Retinal cases & brief reports. 2007.

Valverde D., Riveiro-Alvarez R., Bernal S., Jaakson K., Baiget M., Navarro R., Ayuso C., "Microarray-based mutation analysis of the ABCA4 gene in Spanish patients with Stargardt disease: evidence of a prevalent mutated allele". Mol Vis 2006, Aug11,12:9028.

Adan A., Casaroli-Marano R.P., Gris O., Navarro R., Bitrian E., Pelegrin L., Sanchez-Dalmau B. "Pathological findings in the lens capsules and intraocular lens in chronic pseudophakic endophthalmitis: an electron microscopy study". Eye. 2006.
A. Adán, M. Solé, B. Corcostegui, R. Navarro and A. Burés. "Cytological vitreous findings in a patient with infantile neurological cutaneous and articular (CINCA) syndrome": British Journal of Ophthalmology. 2007. 91;121-122

Conferences and courses

Navarro R. (2016) Speaker. Edema macular: situaciones especiales. II Curso Nuevos horizontes en el diagnóstico y tratamiento del edema macular. Barcelona

Navarro R. (2016) Poster. "Clinical and molecular characterization of the ABCA4-associated dystrophies: novel genotype-phenotype correlations". European Society Human genetics (ESHG) Conference. Barcelona

Navarro R. (2016) Panelist. Discussion of DRCR.net clinical study outcomes. Vision Academy Annual Meeting. Barcelona

Navarro R. (2015) 1) Speaker. 1.Master Class: "Myopic Maculopathies" 2."Cataract surgery in eyes with intermediate stage of AMD". 2) Panelista. Retinamour session. 3) Moderador. Live surgery. 15th Retina Academy. Barcelona

Navarro R. (2015) Speaker. ABCA4: correlación genotipo-fenotipo. Barcelona Retina Meeting. Barcelona

Navarro R. (2015) Clinical cases presentation. Reunión Desafío macular. Madrid

Navarro R. (2015) Poster. Navarro R., Granell M., Hurtado P., Gabarro L. "Impacto de la degeneración macular asociada a la edad en la vida diaria de los pacientes y sus cuidadores". XXXV Jornadas de Economía de la Salud. Granada

Navarro R. (2015) Role of laser in DME. Retinova 2. Madrid

Navarro R. (2015) Speaker. Fluorescein angiography and DME. Allergan Symposium. Encuentro satélite del 5th European Society of Retina Specialists (EURETINA) Winter Meeting. Oxford

Navarro R. (2014). Master Class. Inherited chorioretin- opathies: 14th Retina Academy, Istanbul, Turkey. 2014.

Navarro R. (2014). Speaker. Allergan Advisory Board in Diabetic Macular Oedema. Madrid.

Navarro R. (2014). Speaker. Vision Academy (Bayer) International Steering Committee. Dubai.

Navarro R. (2014). Speaker. Bioimage Study. Euretina Bayer Symposium. London.

Navarro R. (2014). Speaker. ME in macular dystro- phies. New horizon in the diagnosis and treatment of macular oedema. Barcelona.

Navarro R. (2014). Speaker. Protocol Assistance Eu- ropean Medial Agency (EMA). NATAC Pharma clinical trial on Retinitis Pigmentosa. London.

Navarro R. (2014). Speaker. Eylea® Bayer Schering Pharma Advisory Board. Barcelona.

Navarro R. (2013). Speaker. Inherited diffuse retinopa- thies. 7th Symposium on Controversies in Ophthalmol- ogy. Barcelona.

Navarro R. (2013). Speaker. NATAC Pharma steering committee. Saragossa.

Navarro R. (2013). 1) Speaker. Diabetic macular oedema threatening the fovea. 2) Speaker. Retinamour medical retina cases panel discussion. 3) Master Class. Inherited chorioretinopathies 14th Retina Academy. Istanbul.

Navarro R. (2013). Speaker. Long-term treated CNV. International AMD & Retina Congress. Dublin.

Navarro R. (2013). Speaker. DME in proliferative dia- betic retinopathy. International AMD & Retina Con- gress. Dublin.

Navarro R. (2013). Speaker. ARMD and Retinitis Pig- mentosa. Spanish Society of Low Vision Specialists. Barcelona.

Navarro R. (2013). Workshop. Step Spanish Work- shop. National Ophthalmology Scientific Training and Education Programme. Barcelona.

Navarro R. (2013). Workshop. Spanish ARIA Group 2nd Review Meeting. Budapest.

Navarro R. (2013). Speaker. Autofluorescence in clin- ical practice. Ophthalmology Society of the Canary Islands. Tenerife.

Navarro R. (2013). Speaker. Allergan Advisory Board in Diabetic Macular Oedema. Madrid.

Navarro R. (2013). 1) Workshop. Implementing in- dividualized treatment approaches in neovascular AMD: understanding the practical realities. Step 3 International ophthalmology Scientific Training and Education Programme. 2) Workshop. Clinical deci- sion-making in DME 3) Workshop. DME treatment: key considerations and current challenges Rationale for evidence based individualized treatment approaches 4) Workshop. Clinical decision making in neovascular AMD. Dubai.

Navarro R. (2013). Presentation. Fundus autofluores- cence management and diagnosis. Euretina. Ham- burg.

Navarro R. (2013). Presentation. Macular Dystrophies and Autofluorescence. Bilbao.